A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 370 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR The link between Down syndrome and childhood leukaemia September 1, 2022 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 What Happens If More People Get Screened for Cancer? January 26, 2024 Rookie Cop Saves Infant From Choking October 24, 2021 Load more HOT NEWS 5 ways cancer can impact sexual wellbeing Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... FDA Approves Capmatinib for Metastatic NSCLC Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma...
